Business Context and Reporting Period
Company: HEALTHEQUITY, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: June 26, 2025
Event: The Company held its 2025 Annual Meeting of Stockholders and announced a new stock repurchase program.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses on corporate governance actions and capital allocation decisions rather than financial performance results.
Material Changes and Corporate Actions
Stockholder Voting Results
As of the record date (May 7, 2025), 86,630,923 shares were outstanding. Stockholders approved all three proposals:
- Proposal 1 (Election of Directors): All nine nominees were elected. Vote counts ranged from approximately 78.0 million to 79.2 million "For" votes.
- Proposal 2 (Ratification of Auditors): PricewaterhouseCoopers LLP was ratified for the fiscal year ending January 31, 2026, with 82,962,314 "For" votes.
- Proposal 3 (Executive Compensation): The fiscal 2025 executive compensation was approved on an advisory basis with 76,093,619 "For" votes.
Stock Repurchase Program
The Board authorized a new $300 million common stock repurchase program (the "2025 Stock Repurchase Program"). This program supplements the existing $300 million program approved in August 2024. Repurchases may be made via open market purchases or privately negotiated transactions and are subject to market conditions and applicable law.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, outlook, or management commentary regarding future earnings. The Company noted that the repurchase program does not obligate it to purchase any specific dollar amount or number of shares and may be suspended or discontinued at any time.
Investor Verification Checklist
- Verify the total remaining authorization under the combined 2024 and 2025 stock repurchase programs ($600 million total).
- Review the definitive proxy statement (Schedule 14A filed May 13, 2025) for detailed biographies of the newly elected directors and executive compensation specifics.
- Monitor future 8-K filings for the commencement of share repurchases under the new 2025 program.
- Confirm the Company's liquidity position in the next quarterly report (10-Q) to assess capacity for the new $300 million buyback authorization.